(最終更新日:2026-03-06 14:04:15)
  ミゾグチ シンスケ   MIZOGUCHI Shinsuke
  溝口 晋輔
   所属   その他 その他  泌尿器科
   職種   臨床修練生
■ 学術雑誌
1. 原著  Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
2. 原著  Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
3. 原著  Treatment profile of first-line immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma in patients with end-stage renal disease on dialysis. 2026/01
4. 原著  Renal function with enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in Japan. 2025/12
5. 原著  Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma. 2025/10
全件表示(21件)
■ 学会発表
1. Association between enfortumab vedotin and renal function in metastatic urothelial carcinoma:A multicenter retrospective study in Japan. (口頭,一般) 2025/10/25
2. 80歳以上の転移性尿路上皮癌患者に対するパドセブの安全性と有効性について (口頭,一般) 2025/10/17
3. 性別が腎細胞がんに対するニボルマブ・イピリムマブ療法の効果に与えるメカニズム解明 (口頭,一般) 2025/10/16
4. Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. (ポスター掲示,一般) 2025/09/26
5. 網羅的遺伝子発現解析および腫瘍浸潤免疫細胞プロファイリングによる非淡明細胞型腎細胞がんに対する免疫チェックポイント阻害薬治療効果に与える影響の解明 (口頭,一般) 2025/07/05
全件表示(37件)